Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 12, Issue 4, Pages 593-602Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.0c00675
Keywords
Small molecule inhibitor; KCNT1 GoF mutations; HTS; oxadiazole series; SAR; DMPK; K(Na)1.1
Categories
Ask authors/readers for more resources
Variants in the KCNT1 gene lead to neurological disorders like epilepsy without effective treatments. Researchers have developed a novel oxadiazole compound, 31, which can reduce seizures in a mouse model of KCNT1-associated disease.
The gene KCNT1 encodes the sodium-activated potassium channel K(Na)1.1 (Slack, Slo2.2). Variants in the KCNT1 gene induce a gain-of-function (GoF) phenotype in ionic currents and cause a spectrum of intractable neurological disorders in infants and children, including epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Effective treatment options for KCNT1-related disease are absent, and novel therapies are urgently required. We describe the development of a novel class of oxadiazole K(Na)1.1 inhibitors, leading to the discovery of compound 31 that reduced seizures and interictal spikes in a mouse model of KCNT1 GoF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available